发帖
每发1个新帖
可以获得0.5个丁当奖励
回帖

【medical-news】【资讯翻译】欧米珈-3脂肪酸能保护组织心率失常和致死性心脏病的发作

只看楼主
页码直达：
直达末页

楼主

乐清平

肿瘤研究所

常驻站友

1楼

这个帖子发布于8年零20天前，其中的信息可能已发生改变或有所发展。

http://www.medscape.com/viewarticle/754022?src=rss
认领翻译的战友请跟帖注明，"认领本文翻译，48小时内未完成，请其他站友认领"

November 21, 2011 — Patients with diabetes who have experienced a heart attack may get protection from future ventricular arrhythmias and fatal heart attacks by consuming daily recommended doses of omega-3 fatty acids, researchers report in the December issue of Diabetes Care.

The researchers studied the records of 1014 people with diabetes aged 60 to 80 years who had had a heart attack within the previous 10 years. They randomly assigned the patients to 1 of 4 groups: people who received margarines containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 400 mg/d, patients who received margarines containing α-linolenic acid l (ALA) at 2 g/d, patients who received margarines with all 3 fatty acids combined, and patients who received margarines with placebo.

During a 40-month follow-up period, the group that received the combination of all 3 fatty acids experienced an 84% lower incidence of ventricular arrhythmia-related events than the group receiving placebo. That group also experienced a 72% lower incidence of combined arrhythmia and fatal heart attack.

"While more research is needed to definitively determine the role of these fatty acids in protecting people from ventricular arrhythmias, they seem to provide a benefit to the heart attack patients who also had diabetes," lead researcher Daan Kromhout, MPH, PhD, a professor of human nutrition at Wageningen University in the Netherlands, said in a statement. "This is the first study that showed a significant protective effect of Omega-3 fatty acids in high-risk patients with diabetes who were on state-of-the-art drug treatment for their heart attack."

This study was a secondary analysis of the Alpha Omega Trial, a multicenter study involving 32 hospitals in the Netherlands. Previous reports from this trial found no protective link between major cardiovascular events and omega-3 fatty acids for the high-risk patients.

"The key issue to think about is that all of the science — observational science and prior trials — really points to benefits for heart disease death, not total heart disease at low doses [of omega-3 fatty acids]," Dariush Mozaffarian, MD, DrPH, associate professor of epidemiology at the Harvard School of Public Health and associate professor of medicine at Harvard Medical School, Boston, Massachusetts, and an expert on nutrition and prevention of cardiovascular and metabolic diseases, told Medscape Medical News. "That's why this analysis is important, because it looked at a population of diabetes and heart attacks at the very high risk for heart disease."

Dr. Mozaffarian continued: "The strength of it is that they're looking at the right outcome: heart disease death in a high-risk group. The limitation is this is not the original trial, this is a subgroup analysis. It supports the idea that omega-3s are beneficial in people at higher risk for heart disease death, but we would ideally see such results from a larger trial." Larger trials have involved 11,000 and 18,000 participants, he said.

The authors write that a limitation of this study could be the small number of patients who experienced ventricular arrhythmias or died; 29 patients developed arrhythmias, and 50 died of myocardial infarction or other vascular diseases. However, the authors write, the study still showed a significant protective effect for the patients who consumed the combined supplements of EPA, DHA, and ALA. In this, and in the main Alpha Omega Trial, almost all patients were taking antithrombotic prescription drugs, antihypertensive drugs, and statins.

Sources of omega-3 fatty acids include fish and plant oils, walnuts, and supplements.

"At low doses, such as what were studied in this trial, the major established benefits of omega-3s are improved brain function in babies of mothers who are consuming omega-3s and reduced risk of heart disease death," Dr. Mozaffarian said. "Personally, as a cardiologist, I recommend fish consumption as the first, primary, and best approach to getting the omega-3s. Fish has other elements that are good for health, and it's really hard for people to take a pill every day."

The study was funded by the Netherlands Heart Foundation, the US National Institutes of Health (NIH), and Unilever Research and Development. Dr. Kromhout has received grants from the Netherlands Heart Foundation, NIH and Unilever Research and Development. One author has received a grant from the Alpro Foundation, and another author is an employee of Unilever, which markets food products enriched with omega-3 fatty acids. The other study authors have disclosed no other relevant financial relationships. Dr. Mozaffarian has received grants from Pronova ***a, GlaxoSmithKline, and Sigma Tau Pharmaceuticals. He has also received National Institutes of Health funding for an investigator-initiated trial of fish oil to prevent postoperative atrial fibrillation.

邀请讨论

搜索

2011-11-23 11:08 浏览 : 987 回复 : 2

投票
收藏 2
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

ginnyran 编辑于 2011-12-03 16:18

• 12 月首批博士招聘计划：20 省市 65 家单位高薪诚聘博士及博士后

天使猪

科室保密

丁香园荣誉版主

2楼

认领本文翻译，48小时内未完成，请其他战友认领

2011-11-23 12:06

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 医生，我好像咽不下去了!

非常

心血管内科

丁香园准中级站友

+2 积分
3楼

Omega-3 Fatty Acids Protect Against Arrhythmia and Fatal MI

欧米伽-3脂肪酸预防心律失常及致死性心梗

November 21, 2011 — Patients with diabetes who have experienced a heart attack may get protection from future ventricular arrhythmias and fatal heart attacks by consuming daily recommended doses of omega-3 fatty acids, researchers report in the December issue of Diabetes Care.
2011年11月21日--研究人员在12月的《糖尿病护理》指出，经历了心脏病发作的糖尿病患者可通过的每日摄入建议剂量的omega - 3脂肪酸来预防可能的室性心律失常和致命性心脏病发作。
The researchers studied the records of 1014 people with diabetes aged 60 to 80 years who had had a heart attack within the previous 10 years. They randomly assigned the patients to 1 of 4 groups: people who received margarines containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 400 mg/d, patients who received margarines containing α-linolenic acid l (ALA) at 2 g/d, patients who received margarines with all 3 fatty acids combined, and patients who received margarines with placebo.
研究人员研究了1014例在过去10年有心脏病发作的60至80岁的糖尿病人的的纪录。他们把患者随机分为4组，一组每日摄入400毫克二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的人造黄油，一组每日摄入含有2克α-亚麻酸升（ALA）的人造黄油，一组患者的人造黄油含有所有三种脂肪酸，最后一组患者的人造黄油中含有安慰剂。
During a 40-month follow-up period, the group that received the combination of all 3 fatty acids experienced an 84% lower incidence of ventricular arrhythmia-related events than the group receiving placebo. That group also experienced a 72% lower incidence of combined arrhythmia and fatal heart attack.
在40个月的随访期间，摄入所有3种脂肪酸的试验组发生室性心律失常相关事件比安慰剂组的发病率降低84％。这组发生心律失常和致命性心脏病发作的发病率也降低了72％。
"While more research is needed to definitively determine the role of these fatty acids in protecting people from ventricular arrhythmias, they seem to provide a benefit to the heart attack patients who also had diabetes," lead researcher Daan Kromhout, MPH, PhD, a professor of human nutrition at Wageningen University in the Netherlands, said in a statement. "This is the first study that showed a significant protective effect of Omega-3 fatty acids in high-risk patients with diabetes who were on state-of-the-art drug treatment for their heart attack."
“虽然需要更多的研究明确这些脂肪酸在预防室性心律失常的作用，但它们看起来对有心脏病发作史的糖尿病患者有益处，”荷兰Wageningen大学的人类营养学教授，该研究首席研究员Daan Kromhout博士声明。“这是首次研究表明Omega - 3脂肪酸可以有效预防已经进行最佳药物治疗的高危患者的心脏病发作。”
This study was a secondary analysis of the Alpha Omega Trial, a multicenter study involving 32 hospitals in the Netherlands. Previous reports from this trial found no protective link between major cardiovascular events and omega-3 fatty acids for the high-risk patients.
这项研究是阿尔法欧米茄试验的二次分析，是包括荷兰的32家医院的多中心研究。以前的报告没有发现高危患者的主要心血管事件和ω- 3脂肪酸之间的保护相关性。
"The key issue to think about is that all of the science — observational science and prior trials — really points to benefits for heart disease death, not total heart disease at low doses [of omega-3 fatty acids]," Dariush Mozaffarian, MD, DrPH, associate professor of epidemiology at the Harvard School of Public Health and associate professor of medicine at Harvard Medical School, Boston, Massachusetts, and an expert on nutrition and prevention of cardiovascular and metabolic diseases, told Medscape Medical News. "That's why this analysis is important, because it looked at a population of diabetes and heart attacks at the very high risk for heart disease."
“思考的关键问题是，所有的科学 - 观察科学和之前的试验 – 都意味着低剂量欧米伽-3脂肪酸对心脏疾病死亡有益处，而不是对全部心脏病，”美国马萨诸塞州波士顿哈佛大学公共卫生流行病学副教授，哈佛医学院医学副教授，营养和预防心血管疾病和代谢性疾病的专家，Dariush Mozaffarian博士对Medscape医学新闻说。“这就是为什么分析是很重要的，因为该试验是在心脏疾病的风险非常高的有糖尿病和心脏病发作史的人群中进行研究的。”
Dr. Mozaffarian continued: "The strength of it is that they're looking at the right outcome: heart disease death in a high-risk group. The limitation is this is not the original trial, this is a subgroup analysis. It supports the idea that omega-3s are beneficial in people at higher risk for heart disease death, but we would ideally see such results from a larger trial." Larger trials have involved 11,000 and 18,000 participants, he said.
Mozaffarian博士继续说：“它的长处是他们正在寻找正确的结果：高危人群的心脏病死亡。该试验的局限是，这不是原创的试验，而是一个亚组分析。虽然试验结果支持ω- 3脂肪酸有益于心脏疾病死亡的风险较高的人，但我们从一个更大的试验看到这样的结果会更理想。”大规模的试验应该包括11000和18000人参加，他说。
The authors write that a limitation of this study could be the small number of patients who experienced ventricular arrhythmias or died; 29 patients developed arrhythmias, and 50 died of myocardial infarction or other vascular diseases. However, the authors write, the study still showed a significant protective effect for the patients who consumed the combined supplements of EPA, DHA, and ALA. In this, and in the main Alpha Omega Trial, almost all patients were taking antithrombotic prescription drugs, antihypertensive drugs, and statins.
作者写道这项研究的缺陷可能是只有少数病人发生了室性心律失常或死亡；29例患者发生了心律失常，50例死于心肌梗死或其他血管疾病。然而这项研究仍然表现出摄入EPA，DHA和ALA复合制剂对患者显著的保护作用。在这个研究及大的阿尔法欧米茄试验中，几乎所有的患者都服用抗血栓处方药，降压药，他汀类药物。
Sources of omega-3 fatty acids include fish and plant oils, walnuts, and supplements.
ω- 3脂肪酸的来源包括鱼类和植物油，核桃，和补充剂。
"At low doses, such as what were studied in this trial, the major established benefits of omega-3s are improved brain function in babies of mothers who are consuming omega-3s and reduced risk of heart disease death," Dr. Mozaffarian said. "Personally, as a cardiologist, I recommend fish consumption as the first, primary, and best approach to getting the omega-3s. Fish has other elements that are good for health, and it's really hard for people to take a pill every day."
Mozaffarian博士说：“使用如在本试验中的低剂量Omega - 3的主要好处是通过母亲摄入提高婴儿大脑功能，降低心脏疾病死亡的风险”。“就个人而言，作为一个心脏病专家，我强力推荐通过食用鱼类来获得ω- 3S。鱼类有其它对健康有好处的元素，而每天服用药物还是困难的。“
The study was funded by the Netherlands Heart Foundation, the US National Institutes of Health (NIH), and Unilever Research and Development. Dr. Kromhout has received grants from the Netherlands Heart Foundation, NIH and Unilever Research and Development. One author has received a grant from the Alpro Foundation, and another author is an employee of Unilever, which markets food products enriched with omega-3 fatty acids. The other study authors have disclosed no other relevant financial relationships. Dr. Mozaffarian has received grants from Pronova ***a, GlaxoSmithKline, and Sigma Tau Pharmaceuticals. He has also received National Institutes of Health funding for an investigator-initiated trial of fish oil to prevent postoperative atrial fibrillation.

这项研究是由荷兰心脏基金会，美国国立卫生研究院（NIH），和联合利华研究与发展部资助。 Kromhout博士已收到来自荷兰心脏基金会，国立卫生研究院和联合利华研究与发展部的资助金。一位作者收到从阿波罗基金会的资金，另一位作者是联合利华的员工他销售富含与ω- 3脂肪酸的食品。其他研究作者显示没有其他相关财务关系。 Mozaffarian博士已收到Pronova 制药，葛兰素史克公司，和SigmaTau制药资助。他还获得美国国立卫生研究院的一项研究者主导型临床实验资助，研究鱼油对防止术后房颤的效果。

欧米伽-3脂肪酸预防心律失常及致死性心梗（1518字）

2011年11月21日--研究人员在12月的《糖尿病护理》指出，经历了心脏病发作的糖尿病患者可通过的每日摄入建议剂量的omega - 3脂肪酸来预防可能的室性心律失常和致命性心脏病发作。

研究人员研究了1014例在过去10年有心脏病发作的60至80岁的糖尿病人的的纪录。他们把患者随机分为4组，一组每日摄入400毫克二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的人造黄油，一组每日摄入含有2克α-亚麻酸升（ALA）的人造黄油，一组患者的人造黄油含有所有三种脂肪酸，最后一组患者的人造黄油中含有安慰剂。

在40个月的随访期间，摄入所有3种脂肪酸的试验组发生室性心律失常相关事件比安慰剂组的发病率降低84％。这组发生心律失常和致命性心脏病发作的发病率也降低了72％。

“虽然需要更多的研究明确这些脂肪酸在预防室性心律失常的作用，但它们看起来对有心脏病发作史的糖尿病患者有益处，”荷兰Wageningen大学的人类营养学教授，该研究首席研究员Daan Kromhout博士声明。“这是首次研究表明Omega - 3脂肪酸可以有效预防已经进行最佳药物治疗的高危患者的心脏病发作。”

这项研究是阿尔法欧米茄试验的二次分析，是包括荷兰的32家医院的多中心研究。以前的报告没有发现高危患者的主要心血管事件和ω- 3脂肪酸之间的保护相关性。

“思考的关键问题是，所有的科学 - 观察科学和之前的试验 – 都意味着低剂量欧米伽-3脂肪酸对心脏疾病死亡有益处，而不是对全部心脏病，”美国马萨诸塞州波士顿哈佛大学公共卫生流行病学副教授，哈佛医学院医学副教授，营养和预防心血管疾病和代谢性疾病的专家，Dariush Mozaffarian博士对Medscape医学新闻说。“这就是为什么分析是很重要的，因为该试验是在心脏疾病的风险非常高的有糖尿病和心脏病发作史的人群中进行研究的。”

Mozaffarian博士继续说：“它的长处是他们正在寻找正确的结果：高危人群的心脏病死亡。该试验的局限是，这不是原创的试验，而是一个亚组分析。虽然试验结果支持ω- 3脂肪酸有益于心脏疾病死亡的风险较高的人，但我们从一个更大的试验看到这样的结果会更理想。”大规模的试验应该包括11000和18000人参加，他说。

作者写道这项研究的缺陷可能是只有少数病人发生了室性心律失常或死亡；29例患者发生了心律失常，50例死于心肌梗死或其他血管疾病。然而这项研究仍然表现出摄入EPA，DHA和ALA复合制剂对患者显著的保护作用。在这个研究及大的阿尔法欧米茄试验中，几乎所有的患者都服用抗血栓处方药，降压药，他汀类药物。

ω- 3脂肪酸的来源包括鱼类和植物油，核桃，和补充剂。

Mozaffarian博士说：“使用如在本试验中的低剂量Omega - 3的主要好处是通过母亲摄入提高婴儿大脑功能，降低心脏疾病死亡的风险”。“就个人而言，作为一个心脏病专家，我强力推荐通过食用鱼类来获得ω- 3S。鱼类有其它对健康有好处的元素，而每天服用药物还是困难的。”

这项研究是由荷兰心脏基金会，美国国立卫生研究院（NIH），和联合利华研究与发展部资助。 Kromhout博士已收到来自荷兰心脏基金会，国立卫生研究院和联合利华研究与发展部的资助金。一位作者收到从阿波罗基金会的资金，另一位作者是联合利华的员工他销售富含与ω- 3脂肪酸的食品。其他研究作者显示没有其他相关财务关系。 Mozaffarian博士已收到Pronova 制药，葛兰素史克公司，和SigmaTau制药资助。他还获得美国国立卫生研究院的一项研究者主导型临床实验资助，研究鱼油对防止术后房颤的效果。

2011-11-26 22:30

投票 1
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 造影剂过敏

科技动态

【medical-news】【资讯翻译】欧米珈-3脂肪酸能保护组织心率失常和致死性心脏病的发作

提示

丁香园旗下网站

关于丁香园

官方链接

科技动态

分享到：

微信扫一扫

【medical-news】【资讯翻译】欧米珈-3脂肪酸能保护组织心率失常和致死性心脏病的发作

微信扫一扫

微信扫一扫

微信扫一扫

提示

丁香园旗下网站

关于丁香园

官方链接